School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai, Shandong Province, People's Republic of China.
State Key Laboratory of Long-Acting and Targeting Drug Delivery System, Shandong Luye Pharmaceutical Co., Ltd., Yantai, Shandong Province, People's Republic of China.
Eur J Pharm Sci. 2019 Oct 1;138:104990. doi: 10.1016/j.ejps.2019.104990. Epub 2019 Jul 11.
The purpose of this study was to solve the plateau phase (the stage in which the drug in the microsphere undergoes a slow release or almost no release after initial release) problem by understanding the effect of polymer blends on the internal pore changes of the microspheres. This study used PLGA 5050 4H (F-1), PLGA 5050 1A: PLGA 5050 4H = 3:7 (F-2) and PLGA 7525 1A: PLGA 5050 4H = 3:7 (F-3) as a carrier, respectively. Microspheres (MS) were obtained by O/W emulsion solvent evaporation technique and characterized by scanning electron microscopy (SEM), particle size, drug loading, fluorescence characteristics, and in vitro and in vivo release. Accelerated tests in vitro showed that the size and number of core pores significantly affected drug release in the first and second phases. After intramuscular administration, F-2 and F-3 showed effective blood concentration levels and their bioavailability was higher than that of the RLD (Sandostatin Lar). In general, our data indicate that pore formation is unevenly distributed throughout PLGA MS prepared using polymer blends, and the use of polymer blends is instructive for the development of sustained smooth release microspheres. Therefore, the octreotide MS described in this study has a good clinical application potential for the treatment of acromegaly.
本研究旨在通过了解聚合物共混物对微球内部孔结构变化的影响来解决平台期(即微球中药物在初始释放后经历缓慢释放或几乎不释放的阶段)问题。本研究分别使用 PLGA 5050 4H(F-1)、PLGA 5050 1A:PLGA 5050 4H=3:7(F-2)和 PLGA 7525 1A:PLGA 5050 4H=3:7(F-3)作为载体。采用 O/W 乳液溶剂蒸发技术制备微球(MS),并通过扫描电子显微镜(SEM)、粒径、载药量、荧光特性以及体外和体内释放对其进行表征。体外加速试验表明,核心孔的大小和数量显著影响第一和第二阶段的药物释放。肌肉注射后,F-2 和 F-3 表现出有效的血药浓度水平,其生物利用度高于 RLD(Sandostatin Lar)。总体而言,我们的数据表明,使用聚合物共混物制备的 PLGA MS 中孔的形成分布不均匀,聚合物共混物的使用对开发持续平稳释放微球具有指导意义。因此,本研究中描述的奥曲肽 MS 具有治疗肢端肥大症的良好临床应用潜力。